Show pageBacklinksCite current pageExport to PDFBack to top This page is read only. You can view the source, but not change it. Ask your administrator if you think this is wrong. ====== Regorafenib ====== ===== Latest Pubmed Related Articles ===== {{rss>https://pubmed.ncbi.nlm.nih.gov/rss/search/1JUQiFFHYgOpKyzQPPcZ0CmbM1kinq8Usiy_EB_WHRBUMF0wDF/?limit=15&utm_campaign=pubmed-2&fc=20230324081621}} ---- Regorafenib (BAY 73-4506, commercial name Stivarga) is an oral multi-kinase inhibitor developed by Bayer which targets angiogenic, stromal, and oncogenic receptor tyrosine kinase (RTK). Regorafenib shows anti-angiogenic activity due to its dual-targeted VEGFR2-TIE2 tyrosine kinase inhibition. Since 2009 it was studied as a potential treatment option in multiple tumor types. By 2015 it had 2 US approvals for advanced cancers. [[Antiangiogenic]] treatment approaches have failed to improve outcomes in randomized trials of [[high-grade astrocytoma]]. One key mechanism of resistance to antiangiogenic treatment may concern the upregulation of alternative pro-angiogenic pathways. Regorafenib is a potent multikinase inhibitor that may alter some of those pathways ((Tzaridis T, Gepfner-Tuma I, Hirsch S, Skardelly M, Bender B, Paulsen F, Schaub C, Weller J, Schäfer N, Herrlinger U, Tabatabai G. Regorafenib in advanced high-grade glioma: a retrospective bicentric analysis. Neuro Oncol. 2019 Apr 23. pii: noz071. doi: 10.1093/neuonc/noz071. [Epub ahead of print] PubMed PMID: 31089718. )). ====== Side effects ====== [[Regorafenib side effects]] ====== Regorafenib for glioblastoma ====== [[Regorafenib for glioblastoma]]. regorafenib.txt Last modified: 2024/12/16 10:23by 127.0.0.1